The C-terminus of human bleomycin hydrolase is required for protection against bleomycin-induced chromosomal damage

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 421, Issue 1, 1998, Pages 1-7

  Lefterov, Iliya M ^a   Koldamova, Radosveta P ^a   King, Jeremy ^a   Lazo, John S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bleomycin hydrolase; Bleomycin induced chromosomal aberration; C terminal deletion mutant

Indexed keywords

BLEOMYCIN; HYDROLASE;

ARTICLE; CELL CYCLE G2 PHASE; CHO CELL; CHROMATID ABERRATION; CHROMOSOME ABERRATION; CHROMOSOME DAMAGE; DRUG DEGRADATION; HUMAN CELL; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN;

AMINO ACIDS; ANIMALS; BLEOMYCIN; CHO CELLS; CHROMOSOME BREAKAGE; CRICETINAE; CYSTEINE ENDOPEPTIDASES; G2 PHASE; HUMANS; MUTAGENS; SEQUENCE DELETION;

MAMMALIA;

EID: 0032511822     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(98)00148-1     Document Type: Article

References (28)

1. [1] S. Akiyama, K. Ikezaki, H. Kuramochi, K. Takahashi, M. Kuwano, Bleomycin-resistant cells contain increased bleomycin-hydrolase activity, Biochem. Biophys. Res. Commun. 101 (1981) 55-60.
2. [2] S.C. Barranco, R.M. Humphrey, The effects of bleomycin on survival and cell progression in Chinese hamster cells in vitro, Cancer Res. 31 (1971) 1218-1223.
3. [3] P.J. Berti, A.C. Storer, Alignment/phylogeny of the papain superfamily of cysteine proteases, J. Mol. Biol. 246 (1995) 273-283.
4. [4] D. Bromme, A.B. Rossi, S.P. Smeekens, D.C. Anderson, D.G. Payan, Human bleomycin hydrolase - molecular cloning, sequencing, functional expression, and enzymatic characterization, Biochemistry 35 (1996) 6706-6714.
5. [5] J. Cloos, M.R. Spitz, S.P. Schantz, T.C. Hsu, Z.F. Zhang, H. Tobi, B.J. Braakhuis, G.B. Snow, Genetic susceptibility to head and neck squamous cell carcinoma, J. Natl. Cancer Inst. 88 (1996) 530-535.
6. [6] C. Enenkel, D.H. Wolf, BLH1 codes for a yeast thiol aminopeptidase, the equivalent of mammalian bleomycin hydrolase, J. Biol. Chem. 268 (1993) 7036-7043.
7. [7] A.A. Ferrando, A.M. Pendas, E. Llano, G. Velasco, R. Lidereau, C. Lopez-Otin, Gene characterization, promoter analysis, and chromosomal localization of human bleomycin hydrolase, J. Biol. Chem. 272 (1997) 33298-33304.
8. [8] A.A. Ferrando, G. Velasco, E. Campo, C. Lopez-Otin, Cloning and expression analysis of human bleomycin hydrolase, a cysteine proteinase involved in chemotherapy resistance, Cancer Res. 56 (1996) 1746-1750.
9. [9] T.C. Hsu, Genetic predisposition to cancer with special reference to mutagen sensitivity, In Vitro Cell Dev. Biol. 23 (1987) 591-603.
10. [10] T.C. Hsu, X. Wu, Z. Trizna, Mutagen sensitivity in humans. A comparison between two nomenclature systems for recording chromatid breaks, Cancer Genet. Cytogenet. 87 (1996) 127-132.
11. [11] L. Joshua-Tor, H.E. Xu, S.A. Johnston, D.C. Rees, Crystal structure of a conserved protease that binds DNA: the bleomycin hydrolase, Gal6, Science 269 (1995) 945-950.
12. [12] R.P. Koldamova, I.M. Lefterov, V.G. Gadjeva, J.S. Lazo, Essential binding and functional domains of human bleomycin hydrolase, Biochemistry 37 (1997) 2282-2290.
13. [13] M. Kozak, An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs, Nucleic Acids Research 15 (1987) 8125-8148.
14. [14] J.S. Lazo, S.M. Sebti, Bleomycins, in: H.M. Pinedo, D.L. Longo, B.A. Chabner (Eds.), Cancer Chemotherapy and Biological Response Modifiers, Elsevier, Amsterdam. 1997, pp. 40-46.
15. [15] I.M. Lefterov, R.P. Koldamova, Schedule dependent variation in human lymphocyte sensitivity to bleomycin and repair of chromosomal aberrations in G2, Mutat. Res. 284 (1992) 195-204.
16. [16] D. Lopez-Larraza, J.C. De Luca, N.O. Bianchi, The kinetics of DNA damage by bleomycin in mammalian cells, Mutat. Res. 232 (1990) 57-61.
17. [17] R.A. MacLeod, T. Buchheim, M. Kaufmann, H.G. Drexler, Chromosomal breakage correlates with delayed lethality in normal and ataxia telangiectasia cell lines treated with bleomycin, Mutat. Res. 372 (1996) 33-42.
18. [18] S.E. Montoya, R.E. Ferrell, J.S. Lazo, Genomic structure and genetic mapping of the human neutral cysteine protease bleomycin hydrolase, Cancer Res. 57 (1997) 4191-4195.
19. [19] C. Nishimura, H. Suzuki, N. Tanaka, H. Yamaguchi, Intracellular degradation of bleomycin hydrolase in two Chinese hamster cell lines in relation to their peplomycin susceptibility, Biochim. Biophys. Acta 1012 (1989) 29-35.
20. [20] T.K. Pandita, W.N. Hittelman, Evidence of a chromatin basis for increased mutagen sensitivity associated with multiple primary malignancies of the head and neck, Int. J. Cancer 61 (1995) 738-743.
21. [21] Z. Pei, S.M. Sebti, Cys102 and His398 are required for bleomycin-inactivating activity but not for hexamer formation of yeast bleomycin hydrolase, Biochemistry 35 (1996) 10751-10756.
22. [22] S.M. Sebti, J.C. DeLeon, J.S. Lazo, Purification, characterization, and amino acid composition of rabbit pulmonary bleomycin hydrolase, Biochemistry 26 (1987) 4213-4219.
23. [23] S.M. Sebti, J.S. Lazo, Metabolic inactivation of bleomycin analogs by bleomycin hydrolase, Pharmacol. Ther. 38 (1988) 321-329.
24. [24] M.R. Spitz, R.S. McPherson, H. Jiang, T.C. Hsu, Z. Trizna, J.J. Lee, S.M. Lippman, F.R. Khuri, L. Steffen-Batey, R.M. Chamberlain, S.P. Schantz, W.K. Hong, Correlates of mutagen sensitivity in patients with upper aerodigestive tract cancer, Cancer Epidemiol. Biomarkers Prev. 6 (1997) 687-692.
25. [25] H. Umezawa, S. Hori, T. Sawa, T. Yoshioka, T. Takeuchi, A bleomycin-inactivating enzyme in mouse liver, J. Antibiot. 27 (1974) 419-424.
26. [26] Q.Y. Wei, M.R. Spitz, The role of DNA repair capacity in susceptibility to lung cancer - a review, Cancer Metast. Rev. 16 (1997) 295-307.
27. [27] W. Zheng, S.A. Johnston, L. Joshua-Tor, The unusual active site of Gal6/Bleomycin hydrolase can act as a carboxypeptidase, aminopeptidase, and peptide ligase, Cell 93 (1998) 103-109.
28. [28] T.S. Zwanenburg, K. Hansson, F. Darroudi, A.A. van Zeeland, A.T. Natarajan, Effects of 3-aminobenzamide on Chinese hamster cells treated with thymidine analogues and DNA-damaging agents. Chromosomal aberrations, mutations and cell-cycle progression, Mutat. Res. 151 (1985) 251-262.